fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Phase III KEYNOTE-811 trial met dual primary endpoint of overall survival as first-line treatment in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma – Merck

Written by | 9 May 2024

Merck Inc., known as MSD outside of the United States and Canada, announced that the Phase III KEYNOTE-811 trial evaluating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with… read more.

Study confirms pancreatic cancer rates rising faster in women than men

Written by | 14 Feb 2023

In a large-scale nationwide study, investigators from Cedars-Sinai Cancer have confirmed that rates of pancreatic cancer are rising – and are rising faster among younger women, particularly Black women, than… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.